158 related articles for article (PubMed ID: 36997273)
21. Hypereosinophilic syndrome presenting as an unusual triad of eosinophilia, severe thrombocytopenia, and diffuse arterial thromboses, with good response to mepolizumab.
Leon-Ferre RA; Weiler CR; Halfdanarson TR
Clin Adv Hematol Oncol; 2013 May; 11(5):317-9. PubMed ID: 23880717
[No Abstract] [Full Text] [Related]
22. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study.
Gleich GJ; Roufosse F; Chupp G; Faguer S; Walz B; Reiter A; Yancey SW; Bentley JH; Steinfeld J;
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4431-4440.e1. PubMed ID: 34389506
[TBL] [Abstract][Full Text] [Related]
23. Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review.
Nanagas VC; Kovalszki A
Clin Rev Allergy Immunol; 2019 Oct; 57(2):194-212. PubMed ID: 30003499
[TBL] [Abstract][Full Text] [Related]
24. Mepolizumab in eosinophilic disorders.
Abonia JP; Putnam PE
Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
[TBL] [Abstract][Full Text] [Related]
25. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
[TBL] [Abstract][Full Text] [Related]
26. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
Busse WW; Ring J; Huss-Marp J; Kahn JE
J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
[TBL] [Abstract][Full Text] [Related]
27. Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.
Pane F; Lefevre G; Kwon N; Bentley JH; Yancey SW; Steinfeld J
Front Immunol; 2022; 13():935996. PubMed ID: 36091012
[TBL] [Abstract][Full Text] [Related]
28. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
29. Hypereosinophilic syndrome with cutaneous manifestations successfully treated with Dupilumab as a sole agent: A case report.
Scully K; Shao E; Banney L; Weston H
Australas J Dermatol; 2023 Aug; 64(3):400-403. PubMed ID: 37247253
[TBL] [Abstract][Full Text] [Related]
30. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.
Koury MJ; Newman JH; Murray JJ
Am J Med; 2003 Nov; 115(7):587-9. PubMed ID: 14599646
[No Abstract] [Full Text] [Related]
31. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
32. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
Kuruvilla M
Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
[No Abstract] [Full Text] [Related]
33. Benralizumab for
Kuang FL; Legrand F; Makiya M; Ware J; Wetzler L; Brown T; Magee T; Piligian B; Yoon P; Ellis JH; Sun X; Panch SR; Powers A; Alao H; Kumar S; Quezado M; Yan L; Lee N; Kolbeck R; Newbold P; Goldman M; Fay MP; Khoury P; Maric I; Klion AD
N Engl J Med; 2019 Apr; 380(14):1336-1346. PubMed ID: 30943337
[TBL] [Abstract][Full Text] [Related]
34. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome.
Sefcick A; Sowter D; DasGupta E; Russell NH; Byrne JL
Br J Haematol; 2004 Feb; 124(4):558-9. PubMed ID: 14984510
[No Abstract] [Full Text] [Related]
35. An unusual presentation of idiopathic hypereosinophilic syndrome.
Thakral C
Clin Adv Hematol Oncol; 2013 May; 11(5):320-1. PubMed ID: 23880718
[No Abstract] [Full Text] [Related]
36. Novel targeted therapies for eosinophilic disorders.
Wechsler ME; Fulkerson PC; Bochner BS; Gauvreau GM; Gleich GJ; Henkel T; Kolbeck R; Mathur SK; Ortega H; Patel J; Prussin C; Renzi P; Rothenberg ME; Roufosse F; Simon D; Simon HU; Wardlaw A; Weller PF; Klion AD
J Allergy Clin Immunol; 2012 Sep; 130(3):563-71. PubMed ID: 22935585
[TBL] [Abstract][Full Text] [Related]
37. Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab.
Buttgereit T; Bonnekoh H; Church MK; Bergmann KC; Siebenhaar F; Metz M
J Dtsch Dermatol Ges; 2019 Nov; 17(11):1171-1172. PubMed ID: 31479567
[No Abstract] [Full Text] [Related]
38. Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome.
Matucci A; Liotta F; Vivarelli E; Dies L; Annunziato F; Piccinni MP; Nencini F; Pratesi S; Maggi E; Vultaggio A
Front Immunol; 2018; 9():1198. PubMed ID: 29896203
[TBL] [Abstract][Full Text] [Related]
39. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report.
Pitini V; Teti D; Arrigo C; Righi M
Br J Haematol; 2004 Dec; 127(5):477. PubMed ID: 15566349
[No Abstract] [Full Text] [Related]
40. Resolution of a steroid-resistant, hypereosinophilic immune diathesis with mepolizumab and concomitant amelioration of a mixed thrombotic microangiopathy.
Mulvey JJ; Magro C; Chadburn A
Blood Cells Mol Dis; 2018 Mar; 69():38-42. PubMed ID: 28648630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]